Reuters: FDA advisory panel recommends approval of TB Alliance’s tuberculosis treatment
“Independent experts of an FDA advisory panel voted in favor of the not-for-profit TB Alliance’s treatment for drug-resistant tuberculosis, as a part of a three-drug combination regimen. The panel on Tuesday voted 14-4 when asked to assess the treatment, pretomanid, in combination with Johnson & Johnson’s bedaquiline and linezolid for multi-drug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). Although the U.S. health regulator is not bound to follow the advice of its advisory panels, it usually does so…” (Maddipatla/Mathias, 6/6).